ART009

ART009 is a preclinical-stage *in vivo* gene-editing therapeutic candidate being developed by Accuredit Therapeutics for the treatment of metabolic diseases. The program utilizes Accuredit's proprietary gene-editing platform, which is focused on CRISPR-based technologies, to address conditions affecting a large global patient population estimated at 100–200 million. While the specific molecular target and mechanism of action have not been publicly disclosed, the asset is currently in the research and lead optimization phase. The therapy is designed to provide a durable or curative effect by directly modifying genetic drivers of metabolic dysfunction within the patient's body.